Lidocain Accord

Lidocaine, the active ingredient in Lidocain Accord, is a local anesthetic presented as a sterile solution for epidural, intramuscular and intravenous use. It provides reversible loss of sensation for procedures that require regional or procedural analgesia in patients of various ages. GNH USA supplies Lidocain Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocain Accord is a local anesthetic that acts on peripheral nerves to block pain transmission. - Local anesthesia: provides reversible loss of sensation for minor surgical or diagnostic procedures. - Pain management: offers analgesia for acute postoperative or procedural pain. - Regional anesthesia: enables nerve block techniques such as epidural or spinal anesthesia.

Adverse reactions may occur following administration of Lidocain Accord.

Common Side Effects: - Injection site pain: mild discomfort at the site of administration. - Redness or swelling: localized erythema around the injection area. - Transient numbness: temporary loss of sensation extending beyond the intended region. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or anaphylaxis. - Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening. - Seizure: central nervous system excitation leading to convulsions. - Methemoglobinemia: reduced oxygen‑carrying capacity of blood.

Before using Lidocain Accord, consider the following precautions. - Cardiac history: assess for pre‑existing heart disease or conduction abnormalities. - Blood pressure: monitor for hypotension, especially with large doses. - Allergy: avoid in patients with known lidocaine hypersensitivity. - Hepatic function: use caution in severe liver impairment as metabolism may be reduced. - Store at room temperature: keep in the original container, protect from moisture and light.

Lidocain Accord can interact with other medicines; review the following.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may increase cardiotoxicity. - Cimetidine: can raise plasma lidocaine levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers (e.g., propranolol): may enhance hypotensive effects. - Calcium channel blockers (e.g., verapamil): may increase risk of cardiac depression. - CYP3A4 inhibitors (e.g., erythromycin): may modestly raise lidocaine concentrations.